Skip to main content

Table 2 Summary of variables at baseline, 12 weeks, 1 year and 2 years of treatment

From: The effectiveness of Reslizumab in severe asthma treatment: a real-world experience

Variables

Baseline

(N=26)

12 weeks

(N=24)

1 year

(N=22)

2 year2

(N=11)

Mean ACQ-6 score ± SD

3.50 ± 1.1

1.8 ± 1.7

1.7 ± 1.4

1.3 ± 1.1

 Mean improvement in ACQ-6

1.7

1.7

2.0

 P value

<0.0001

0.0001

0.0001

Mean glucocorticoid dosea ± SD

9.29 ± 4.32

4.79 ± 4.07

4.77 ± 4.53

4.62 ± 3.59

 Median reduction in the final oral glucocorticoid-% of baseline value

50%

50%

50%

 Mean reduction of prednisolone dose ± SD

4.50 ± 3.85

5.23 ± 4.80

4.12 ± 4.06

 P Value

0.0008

0.0048

0.0239

Mean percent of FEV1 predicted value (before bronchodilation) +- SD

62.08% ± 19.85

64.51% ± 25.30

70.61% ± 15.40

74.91 ± 22.63

 Mean improvement in FEV1 percent of predicted value

6.28

11.95

12.14

 P value

0.36

0.018

0.0021

Average number of exacerbationsb ± SD

8.32 ± 4.68

1.74 ± 2.13

0.91 ± 0.70

 Mean reduction in annual Exacerbationsb ± SD

7.26 ± 4.74

6.64 ± 3.29

 P Value

<0.0001

<0.0001

Mean peripheral blood Eosinophils countc ± SD

0.78 ± 0.51

0.05 ± 0.03

0.05 ± 0.04

0.04 ± 0.03

 Mean reduction of eosinophils counts

0.73 ± 0.52

0.74 ± 0.57

0.72 ± 0.63

 P Value

<0.0001

<0.0001

0.0057

  1. ACQ-6 Asthma Control Questionnaire, FEV1 Forced Expiratory Volume in 1 second
  2. aPrednisolone dose in mg
  3. bAverage number of exacerbations per year that required rescue systemic steroids course or increase in the maintenance steroid dose
  4. ccells X 109/L